Inhibitors for use in hemostasis and immune function
OwnerPaul O. Sheppard, Gerald W. Lasser +1inventors
InventorsPaul O. Sheppard, Gerald W. Lasser, Paul D. Bishop
Life of this patent
Estimating the term…
Abstract
The present invention relates to polynucleotide and polypeptide molecules for use as inhibitors in hemostasis and immune function. Such inhibitors are members of the family of proteins bearing a collagen-like domain and a globular domain. The inhibitors are useful for promoting blood flow in the vasculature by reducing thrombogenic and complement activity. The inhibitors are also useful for pacify collagenous surfaces and modulating wound healing.
Claims131
A method of promoting blood flow within the vasculature of a mammal comprising administering to said mammal a therapeutically effective amount of an adipocyte complement related protein;
- in a pharmaceutically acceptable vehicle;
- whereby said adipocyte complement related protein reduces thrombogenic and complement activity within said vasculature.
A method of pacifying damaged collagenous tissues within a mammal comprising administering to said mammal a therapeutically effective amount of an adipocyte complement related protein;
- whereby said protein renders the damaged collagenous tissue inert towards complement activation, thrombotic activity or immune activation
A method of pacifying the surface of a prostatic biomaterial for use in association with a mammal comprising administering to said mammal a therapeutically effective amount of an adipocyte complement related protein;
- whereby said polypeptide renders the surface of said prosthetic biomaterial inert towards complement activation, thrombotic activity or immune activation.
A method of mediating wound repair within a mammal comprising administering to said mammal a therapeutically effective amount of an adipocyte complement related protein;
- whereby said polypeptide enhances progression in wound healing.
A method for inhibiting platelet adhesion comprising administering to a patient in need of such inhibition a therapeutically effective amount of an adipocyte complement related protein in a pharmaceutical acceptable vehicle.
A method for inhibiting platelet activation comprising administering to a patient in need of such inhibition a therapeutically effective amount of an adipocyte complement related protein in a pharmaceutical acceptable vehicle.
A method for inhibiting platelet accretion comprising administering to a patient in need of such inhibition a therapeutically effective amount of an adipocyte complement related protein in a pharmaceutical acceptable vehicle.
A method for minimizing vascular occlusion by increasing patency time in a patient in need of such treatment comprising administering an adipocyte complement related protein in a pharmaceutically acceptable vehicle, wherein said adipocyte complement related protein promotes blood flow.
A method for inducing vasodilation within the vasculature of a mammal comprising administrating to said mammal a therapeutically effective amount of an adipocyte complement related protein;
- in a pharmaceutically acceptable vehicle;
- whereby said adipocyte complement related protein elicits a vasorelaxant response.
A method for protecting ischemic myocardium from reperfusion injury comprising administering an adipocyte complement related protein to a patient in need of such protection, wherein said adipocyte complement related protein inhibits complement.
A method for mediating tumor metastasis comprising administering an adipocyte complement related protein to a patient in need of such inhibition, wherein said adipocyte complement related protein mediates tumor cell binding to collagen.
A method for inhibiting platelet adhesion comprising administering to a patient a therapeutically effective amount of a formulation comprising:
- a polypeptide comprising amino acid residues 26 to 281 of SEQ ID NO:
- 2 and;
- a pharmaceutical acceptable vehicle.
A method for inhibiting platelet activation comprising administering to a patient a therapeutically effective amount of a formulation comprising:
- a polypeptide comprising amino acid residues 26 to 281 of SEQ ID NO:
- 2 and;
- a pharmaceutical acceptable vehicle.
A method for inhibiting platelet accretion comprising administering to a patient a therapeutically effective amount of a formulation comprising:
- a polypeptide comprising amino acid residues 26 to 281 of SEQ ID NO:
- 2 and;
- a pharmaceutical acceptable vehicle.
Dependencies are inferred from the claim text.